about
Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle traffickingBone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors.Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors.Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation.Cellular and molecular immune responses of the sea bass (Dicentrarchus labrax) experimentally infected with betanodavirus.Natural Killer Cells: Angels and Devils for Immunotherapy.Effects of stocking density and feed ration on growth and gene expression in the Senegalese sole (Solea senegalensis): potential effects on the immune response.Gene and miRNA expression profiles of hematopoietic progenitor cells vary depending on their origin.Molecular characterization, phylogeny, and expression of c-type and g-type lysozymes in brill (Scophthalmus rhombus).A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT.Genomic characterization and gene expression analysis of four hepcidin genes in the redbanded seabream (Pagrus auriga).Self-renewing human bone marrow mesenspheres promote hematopoietic stem cell expansion.Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.Immunotherapy: A Novel Era of Promising Treatments for Multiple MyelomaCAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer PatientsDevelopment of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic InstitutionsOverexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid LeukemiaA constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCTA novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphismsExtracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptorPreclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myelomaNectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma
P50
Q27331909-AF32D8FA-3D17-4520-828A-9876EEE74C87Q33828556-57EF0772-F3B3-4650-919D-CC27EDA8C218Q34375340-35CF7C00-6146-4E87-B77A-CABF3237E56DQ34451574-5D5A1311-C5BB-41F4-9A69-C48B375A1C4BQ35034803-6A6248C9-0C4A-4A57-95E6-EBA7448A1116Q35809966-E7BD4D16-F647-4E2D-BF23-F9E02D0A79DEQ37552014-3C2382DE-DE09-459D-8402-C0D046ABD6DDQ37810124-B586F3B7-6068-44B5-94BF-21A7E2416F07Q39772714-CCCC6E79-910E-47C3-AD10-34B034DB291FQ41661175-A57CAD43-FACE-44C4-8167-AF3EE6398325Q43243375-66EA709E-F34A-4294-9700-869E0289D238Q44045369-818BD4B3-8097-442A-9680-87D113FFE55AQ45822418-54200221-83DB-4A98-9AF2-63B490E2FC02Q46031355-767024CB-9AAC-48DB-BEAE-F3BC471D13D2Q46064228-99E2A816-CC04-4A96-BCAD-7087BD329B7AQ51036755-FC94607F-6AF3-418A-A1F9-3117B6A87DA9Q52659565-86D48814-019D-4D40-95E0-08D6968DFD9CQ54684351-4153F426-6B51-4034-8700-C9F293F13D26Q59801829-815AFFF8-1A7E-4D69-919F-A812A5CD3493Q59809431-92D5C05C-A532-4780-B8DD-02D856214C13Q60912961-E513234D-22A0-460A-8EA0-56D470F829F3Q63253922-66B60668-1822-470E-BD61-802FBCD1ED37Q63253927-2AA3C3DD-8BDF-4460-B8E9-23FE29000C3BQ90374351-8354A6E4-F7BF-44B2-AAC9-9C9F029FCBABQ90751799-D7DE99D7-8FDE-46E7-8A3F-33ABBFA45359Q92525435-B2E67690-FECC-4E52-8964-382CA6F8FB8DQ96229953-1FED637C-AE72-45E2-9441-21E607852998
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Beatriz Martín-Antonio
@ast
Beatriz Martín-Antonio
@en
Beatriz Martín-Antonio
@es
Beatriz Martín-Antonio
@nl
Beatriz Martín-Antonio
@sl
type
label
Beatriz Martín-Antonio
@ast
Beatriz Martín-Antonio
@en
Beatriz Martín-Antonio
@es
Beatriz Martín-Antonio
@nl
Beatriz Martín-Antonio
@sl
prefLabel
Beatriz Martín-Antonio
@ast
Beatriz Martín-Antonio
@en
Beatriz Martín-Antonio
@es
Beatriz Martín-Antonio
@nl
Beatriz Martín-Antonio
@sl
P108
P1053
D-4963-2014
P106
P21
P31
P3829
P496
0000-0003-0612-2693